PT  - JOURNAL ARTICLE
AU  - Michael Hultström
AU  - Karin Fromell
AU  - Anders Larsson
AU  - Susan E Quaggin
AU  - Christer Betsholtz
AU  - Robert Frithiof
AU  - Miklos Lipcsey
AU  - Marie Jeansson
TI  - Elevated Angiopoietin-2 inhibits thrombomodulin-mediated anticoagulation in critically ill COVID-19 patients
AID  - 10.1101/2021.01.13.21249429
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.01.13.21249429
4099  - http://medrxiv.org/content/early/2021/05/27/2021.01.13.21249429.short
4100  - http://medrxiv.org/content/early/2021/05/27/2021.01.13.21249429.full
AB  - Several studies suggest that hypercoagulation and endothelial dysfunction play central roles in severe forms of COVID-19 infections. We hypothesized that the high levels of the inflammatory cytokine Angiopoietin-2 (ANGPT2) reported in hospitalized COVID-19 patients might promote hypercoagulation through ANGPT2 binding to thrombomodulin with resulting inhibition of thrombin/thrombomodulin-mediated physiological anticoagulation. Plasma was collected from critically ill COVID-19 patients treated in the intensive care unit (ICU) at Uppsala University Hospital and ANGPT2 was measured at admission (61 patients) and after ten days (40 patients). ANGPT2 levels were compared with biochemical parameters, clinical outcome, and survival. We found that ANGPT2 levels were increased in COVID-19 patients in correlation with disease severity, hypercoagulation, and mortality. To test causality, we administered ANGPT2 to wildtype mice and found that it shortened bleeding time in a tail injury model. In further support of a role for ANGPT2 in physiological coagulation, bleeding time was increased in endothelial-specific Angpt2 knockout mice. Using in vitro assays, we found that ANGPT2 inhibited thrombomodulin-mediated anticoagulation and protein C activation in human donor plasma. Our data reveal a novel mechanism for ANGPT2 in hypercoagulation and suggest that Angiopoietin-2 inhibition may be tested in the treatment of hypercoagulation in severe COVID-19 infection.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04316884Funding StatementThe study was funded by the SciLifeLab/KAW national COVID-19 research program project grant to MH (KAW 2020.0182 and KAW2020.0241), the Swedish Heart-Lung Foundation to MH (20210089) the Swedish Research Council grant to RF (2014-02569 and 2014-07606), and Swedish Research Council grant (2012-865), Ake Wiberg Foundation, Magnus Bergwall Foundation, IGP Young Investigator Award to MJ. The laboratory of C.B. is funded by grants from the Swedish Research Council, the Swedish Cancer Society, and the Knut and Alice Wallenberg Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Swedish National Ethical Review Agency (EPM; No. 2020-01623). Informed consent was obtained from the patient, or next of kin if the patient was unable to give consent. Healthy blood donor samples were approved under ethical permit No 01/367. The Declaration of Helsinki and its subsequent revisions were followed. The protocol for the study was registered (ClinicalTrials ID: NCT04316884); STROBE guidelines were followed for reporting. All animal experiments were approved by the Uppsala Committee of Ethics of Animal Experiments (approved permit number 5.8.18-04862-2020 and 5.8.18-03858-2021) and were conducted according to guidelines established by the Swedish Board of Agriculture. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are presented within the manuscript